These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 17533166)

  • 1. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
    Arrivé E; Newell ML; Ekouevi DK; Chaix ML; Thiebaut R; Masquelier B; Leroy V; Perre PV; Rouzioux C; Dabis F;
    Int J Epidemiol; 2007 Oct; 36(5):1009-21. PubMed ID: 17533166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
    Samuel R; Paredes R; Parboosing R; Moodley P; Singh L; Naidoo A; Gordon M
    J Med Virol; 2015 Oct; 87(10):1662-7. PubMed ID: 25940687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique.
    Antunes F; Zindoga P; Gomes P; Augusto O; Mahumane I; Veloso L; Valadas E; Camacho R
    PLoS One; 2015; 10(7):e0131994. PubMed ID: 26161559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
    Persaud D; Bedri A; Ziemniak C; Moorthy A; Gudetta B; Abashawl A; Mengistu Y; Omer SB; Isehak A; Kumbi S; Adamu R; Lulseged S; Ashworth R; Hassen E; Ruff A;
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):823-9. PubMed ID: 21241214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    Kurle SN; Gangakhedkar RR; Sen S; Hayatnagarkar SS; Tripathy SP; Paranjape RS
    AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
    Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Brocklehurst P; Volmink J
    Cochrane Database Syst Rev; 2002; (2):CD003510. PubMed ID: 12076484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Brocklehurst P; Volmink J
    Cochrane Database Syst Rev; 2002; (1):CD003510. PubMed ID: 11869666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    Eshleman SH; Mracna M; Guay LA; Deseyve M; Cunningham S; Mirochnick M; Musoke P; Fleming T; Glenn Fowler M; Mofenson LM; Mmiro F; Jackson JB
    AIDS; 2001 Oct; 15(15):1951-7. PubMed ID: 11600822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
    Frank M; von Kleist M; Kunz A; Harms G; Schütte C; Kloft C
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5529-40. PubMed ID: 21947390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine resistance after single dose prophylaxis.
    Eshleman SH; Jackson JB
    AIDS Rev; 2002; 4(2):59-63. PubMed ID: 12152519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
    van Zyl GU; Claassen M; Engelbrecht S; Laten JD; Cotton MF; Theron GB; Preiser W
    J Med Virol; 2008 Jun; 80(6):942-6. PubMed ID: 18428139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    Toni TD; Masquelier B; Lazaro E; Dore-Mbami M; Ba-Gomis FO; Téa-Diop Y; Kouakou K; Diby J; Sia E; Soppi S; Essien S; Schrive MH; Pinson P; Chenal H; Fleury HJ
    AIDS Res Hum Retroviruses; 2005 Dec; 21(12):1031-4. PubMed ID: 16379606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
    Chaix ML; Ekouevi DK; Peytavin G; Rouet F; Tonwe-Gold B; Viho I; Bequet L; Amani-Bosse C; Menan H; Leroy V; Rouzioux C; Dabis F
    Antimicrob Agents Chemother; 2007 Mar; 51(3):896-901. PubMed ID: 17178792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.
    Giaquinto C; Rampon O; De Rossi A
    Clin Drug Investig; 2006; 26(11):611-27. PubMed ID: 17163296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
    Eshleman SH; Guay LA; Mwatha A; Cunningham SP; Brown ER; Musoke P; Mmiro F; Jackson JB
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):595-9. PubMed ID: 15242535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.